ALK-positive non-small-cell lung cancer

What changed: ALK-positive non-small-cell lung cancer

Cancer page →

Every dated change on the records linked to ALK-positive non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval6Regulatory2Trial result5Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordALK-positive non-small-cell lung cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025Trial resultALKOVE-1
ALKOVE-1 reported
ORR 31% in heavily pretreated ALK+ NSCLC; NDA under priority review.

2024 · 2

2023 · 2

March 2021 · 1

2021-03-03RegulatoryLorlatinib
Lorlatinib: approval (US)
First-line ALK+ NSCLC (CROWN); full approval

2021 · 1

2021ApprovalLorlatinib
Lorlatinib approved in US
First-line ALK+ NSCLC

2020 · 2

November 2018 · 1

2018-11-02RegulatoryLorlatinib
Lorlatinib: approval (US)
ALK+ NSCLC after prior ALK TKIs (accelerated)

2018 · 3

2017 · 3

2015 · 1

2015ApprovalAlectinib
Alectinib approved in US
ALK+ NSCLC after crizotinib

2014 · 1

2014MilestoneCrizotinib
PROFILE 1014: crizotinib beats chemotherapy first line
A milestone in how this cancer is treated.

2011 · 1

2011MilestoneCrizotinib
Crizotinib approved four years after the fusion was found
A milestone in how this cancer is treated.

2007 · 1

2007MilestoneALK
EML4-ALK fusion discovered in lung cancer (Soda and Mano, Japan)
A milestone in how this cancer is treated.